<DOC>
	<DOCNO>NCT01100684</DOCNO>
	<brief_summary>The purpose study determine whether asimadoline safe effective treat D-IBS .</brief_summary>
	<brief_title>Study Asimadoline Treat Diarrhea-Predominant Irritable Bowel Syndrome ( D-IBS )</brief_title>
	<detailed_description>The primary objective study compare efficacy two treatment respect improvement IBS-related abdominal pain severity reduction stool frequency . During 12-week treatment period , daily IBS-related abdominal pain severity score daily frequency bowel movement average week determine average value endpoint . For subject , weekly response treatment base follow parameter : - Decrease baseline least 30 % average IBS-related daily abdominal pain severity score - Decrease baseline least 25 % average number daily bowel movement A subject must meet criterion consider weekly responder . The primary efficacy endpoint base `` overall study responder , '' define subject 6 week weekly response treatment 12 week treatment period . Overall study responder stratify time bowel preparation endoscopy .</detailed_description>
	<mesh_term>Syndrome</mesh_term>
	<mesh_term>Diarrhea</mesh_term>
	<mesh_term>Irritable Bowel Syndrome</mesh_term>
	<criteria>1 . Signs date write informed consent form . 2 . Male female subject age 1879 fluent English 3 . All subject must use protocol specify contraceptive measure 4 . The subject diagnose IBS symptom onset least 6 month prior diagnosis . IBS define subject recurrent abdominal pain discomfort least 3 day per month past 3 month associate least two follow symptom : Improvement defecation Onset associate change frequency stool Onset associate change form ( appearance ) stool 5 . The subject diagnose diarrheapredominant IBS 6 . Within 2 year randomization visit , subject normal result flexible sigmoidoscopy , colonoscopy , barium enema plus flexible sigmoidoscopy , accord subject 's age specify algorithm . 1 . The subject exhibit evidence biochemical structural abnormality digestive tract . 2 . Subject concurrent illness disability ( exclude IBS ) may affect interpretation clinical efficacy and/or safety data otherwise contraindicate participation clinical study ( e.g. , unstable cardiovascular , renal , hepatic , pulmonary , endocrine , metabolic , GI , hematological , neurological condition ) . 3 . The subject family history prolong QT syndrome . 4 . The subject diagnose major psychiatric disorder . 5 . The subject history alcohol substance abuse within past 2 year . 6 . The subject history current evidence laxative abuse 7 . The subject positive stool sample ovum parasite . 8 . The subject use investigational drug participate investigational study within 30 day screen . 9 . The subject refuse discontinue one ( ) prohibit medication least 7 day prior screen visit . 10 . The subject refuse maintain stable dose one ( ) allowable concurrent medication least 30 day prior screen visit . 11 . The subject pregnant woman woman breast feeding . 12 . The subject unable unwilling follow direction use electronic diary system .</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>79 Years</maximum_age>
	<verification_date>December 2013</verification_date>
	<keyword>diarrhea predominant irritable bowel syndrome</keyword>
</DOC>